1. Home
  2. DTSS vs BLRX Comparison

DTSS vs BLRX Comparison

Compare DTSS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Datasea Inc.

DTSS

Datasea Inc.

HOLD

Current Price

$0.87

Market Cap

7.4M

Sector

Technology

ML Signal

HOLD

Logo BioLineRx Ltd.

BLRX

BioLineRx Ltd.

HOLD

Current Price

$2.59

Market Cap

12.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DTSS
BLRX
Founded
2014
2003
Country
China
Israel
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4M
12.0M
IPO Year
2026
2010

Fundamental Metrics

Financial Performance
Metric
DTSS
BLRX
Price
$0.87
$2.59
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $19.00
AVG Volume (30 Days)
★ 5.9M
19.9K
Earning Date
05-14-2026
05-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$2.15
52 Week High
$2.29
$4.56

Technical Indicators

Market Signals
Indicator
DTSS
BLRX
Relative Strength Index (RSI) 55.22 47.03
Support Level $0.71 $2.18
Resistance Level $0.97 $3.04
Average True Range (ATR) 0.18 0.12
MACD 0.03 0.01
Stochastic Oscillator 20.10 38.89

Price Performance

Historical Comparison
DTSS
BLRX

About DTSS Datasea Inc.

Datasea Intelligent Technology Ltd, formerly known as Datasea Inc, is a technology company that operates in two main segments. The first segment, Acoustic High-Tech, focuses on developing and applying acoustic technologies, such as ultrasound, infrasound, and mechanical wave effects, for applications like ultrasonic sterilization, neuro-regulation, acupoint stimulation, and environmental purification. The second segment, AI Multimodal Digitalization, integrates artificial intelligence with 5G networks and big data processing to create a proprietary multimodal data platform that combines text, voice, image, and video for real-time intelligent analysis and generation. The company generates all of its revenue from the People's Republic of China (PRC).

About BLRX BioLineRx Ltd.

BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Share on Social Networks: